Tectonic Therapeutic (TECX) Non-Current Deferred Tax Liability (2018 - 2024)
Tectonic Therapeutic's (TECX) quarterly Non-Current Deferred Tax Liability came in at $40.3 million in Q4 2024, up 16832.77% on a QoQ basis from $238000.0 in Q4 2018.
Tectonic Therapeutic (TECX) Non-Current Deferred Tax Liability (2018 - 2024) Analysis & Trends
Tectonic Therapeutic (TECX) has 2 years of Non-Current Deferred Tax Liability data on file, last reported at $40.3 million in Q4 2024.
- On a quarterly basis, Non-Current Deferred Tax Liability changed N/A year-over-year to $40.3 million in Q4 2024; TTM through Dec 2024 was $40.3 million, a N/A change from a year earlier, with the FY2024 full-year figure at $40.3 million, changed N/A from the prior year.
- Non-Current Deferred Tax Liability for Q4 2024 stood at $40.3 million, up from $238000.0 in the prior quarter.
- Over the last five years, Non-Current Deferred Tax Liability for TECX reached as high as $40.3 million in Q4 2024 and fell as low as $40.3 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Tectonic Therapeutic | 595.23 Mn | 595.23 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 40.30 Mn |
| Dec 31, 2024 | 40.30 Mn |
| Dec 31, 2018 | 238,000.00 |
| Dec 31, 2018 | 238,000.00 |